1. Home
  2. DCTH vs BWAY Comparison

DCTH vs BWAY Comparison

Compare DCTH & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DCTH

Delcath Systems Inc.

N/A

Current Price

$15.41

Market Cap

578.4M

Sector

Health Care

ML Signal

N/A

Logo BrainsWay Ltd.

BWAY

BrainsWay Ltd.

N/A

Current Price

$12.60

Market Cap

547.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DCTH
BWAY
Founded
1988
2003
Country
United States
Israel
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
578.4M
547.7M
IPO Year
2015
2011

Fundamental Metrics

Financial Performance
Metric
DCTH
BWAY
Price
$15.41
$12.60
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
3
Target Price
★ $24.00
$19.27
AVG Volume (30 Days)
★ 281.2K
77.2K
Earning Date
11-03-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 107.53
N/A
EPS
★ 0.04
N/A
Revenue
N/A
N/A
Revenue This Year
$24.61
$32.42
Revenue Next Year
$24.27
$23.40
P/E Ratio
$396.00
★ $81.98
Revenue Growth
N/A
N/A
52 Week Low
$8.12
$11.77
52 Week High
$17.42
$26.63

Technical Indicators

Market Signals
Indicator
DCTH
BWAY
Relative Strength Index (RSI) 49.59 31.45
Support Level $15.68 $11.90
Resistance Level $16.51 $14.83
Average True Range (ATR) 0.43 0.55
MACD -0.09 -0.02
Stochastic Oscillator 48.67 0.61

Price Performance

Historical Comparison
DCTH
BWAY

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

About BWAY BrainsWay Ltd.

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

Share on Social Networks: